Nordic Nanovector ASA | Mutual Funds
Mutual Funds that own Nordic Nanovector ASA
756,601
1.54%
0
1.33%
09/06/2018
Nordea Kapital
514,468
1.05%
56,980
0.59%
01/31/2018
KLP AksjeNorge Indeks
384,930
0.78%
0
0.18%
08/31/2018
KLP AksjeNorge
300,000
0.61%
0
0.24%
08/31/2018
Gladiator
300,000
0.61%
300,000
0.39%
12/31/2016
Storebrand Indeks - Norge
199,879
0.41%
0
0.18%
08/31/2018
DFA Continental Small Company Series
197,914
0.4%
19,427
0.02%
01/31/2018
iShares MSCI EAFE Small Cap ETF
191,229
0.39%
0
0.01%
09/06/2018
161,255
0.33%
2,020
0.45%
09/06/2018
DNB Norge Indeks
159,121
0.32%
5,636
0.19%
07/31/2018
| Address |
Kjelsasveien 168 B
Oslo PS 0884
Norway
|
|
Employees
|
- |
| Website |
http://www.nordicnanovector.com |
| Updated |
07/08/2019 |
| Nordic Nanovector ASA engages in the provision of development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers such as non-Hodgkin's Lymphoma and leukaemia. It offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. Nordic Nanovector operates its business through the following geographical segments: Norway, Switzerland, and the United Kingdom. |
